恒瑞医药口服减重新药获批临床

健识局01-14

1月12日晚间，恒瑞医药发布公告称，公司子公司山东盛迪医药有限公司收到国家药品监督管理局（NMPA）核准签发关于HRS-7535片的《药物临床试验批准通知书》，将于近期开展临床试验，申请的适应症：本品拟用于高血压合并超重或肥胖治疗。目前全球范围内尚无口服小分子GLP-1R激动剂上市。公告显示，HRS-7535片是一种新型口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂，既可以通过激活人的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2603612637?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-14 19:08","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2603612637","market":"hk","top_or_hot":-1,"title":"恒瑞医药口服减重新药获批临床","media":"健识局","content":"<div>\n<p>1月12日晚间，恒瑞医药发布公告称，公司子公司山东盛迪医药有限公司收到国家药品监督管理局（NMPA）核准签发关于HRS-7535片的《药物临床试验批准通知书》，将于近期开展临床试验，申请的适应症：本品拟用于高血压合并超重或肥胖治疗。目前全球范围内尚无口服小分子GLP-1R激动剂上市。公告显示，HRS-7535片是一种新型口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂，既可以通过激活人的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114192555a71a0828&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药口服减重新药获批临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药口服减重新药获批临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-14 19:08 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114192555a71a0828&s=b><strong>健识局</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1月12日晚间，恒瑞医药发布公告称，公司子公司山东盛迪医药有限公司收到国家药品监督管理局（NMPA）核准签发关于HRS-7535片的《药物临床试验批准通知书》，将于近期开展临床试验，申请的适应症：本品拟用于高血压合并超重或肥胖治疗。目前全球范围内尚无口服小分子GLP-1R激动剂上市。公告显示，HRS-7535片是一种新型口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂，既可以通过激活人的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114192555a71a0828&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114192555a71a0828&s=b","article_id":"2603612637","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114192555a71a0828&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603612637","pubTimestamp":1768388918,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"1月12日晚间，恒瑞医药发布公告称，公司子公司山东盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-7535片的《药物临床试验批准通知书》，将于近期开展临床试验，申请的适应症：本品拟用于高血压合并超重或肥胖治疗。目前全球范围内尚无口服小分子GLP-1R激动剂上市。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01276":"恒瑞医药","LU0359201612.USD":"贝莱德中国基金A2","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","BK1191":"制药"},"translate_title":"Hengrui Medicine's oral reducing drug was approved for clinical treatment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1.5},"content_text":"1月12日晚间，恒瑞医药发布公告称，公司子公司山东盛迪医药有限公司收到国家药品监督管理局（NMPA）核准签发关于HRS-7535片的《药物临床试验批准通知书》，将于近期开展临床试验，申请的适应症：本品拟用于高血压合并超重或肥胖治疗。目前全球范围内尚无口服小分子GLP-1R激动剂上市。公告显示，HRS-7535片是一种新型口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂，既可以通过激活人的GLP-1R，促进胰腺的胰岛素分泌和降低胰高血糖素分泌并抑制胃排空，还可以通过影响中枢增强饱腹感和抑制食欲，直接减少能量的摄入等机制用于治疗2型糖尿病（T2DM）和减重。运营｜李木子最火双抗大卖56亿美元，跨国药企“厮杀”在中国市场礼来X英伟达，砸10亿美元，AI制药板块“炸”了！艾伯维押注荣昌生物RC148，双抗赛道迎来新变局","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603612637","isCrawlerRequest":true}